Gadoquatrane (BAY1747846)
Sponsors
Bayer
Conditions
Central Nervous System PathologyChildrenContrast Enhancement in Magnetic Resonance ImagingNon-central Nervous System Pathology
Phase 2
Phase 3
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)
CompletedNCT05915026
Start: 2023-08-16End: 2024-10-16Updated: 2025-08-01
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
CompletedNCT05915702
Start: 2023-07-24End: 2024-05-31Updated: 2025-08-17
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
CompletedNCT05915728
Start: 2023-07-24End: 2024-06-01Updated: 2025-12-22